Development of recombinant Adeno-Associated Viral vector (rAAV) for passive immunisation against ebola

Domain:

healthcare

Record type:

paper

Creator:

TanRijTowHyd

Publisher:

Host:

The 2014-2016 Ebola outbreak in West Africa was the largest in history leading to 28,639 cases, of which 40% were fatal. Better treatments and effective vaccines against Ebola virus are needed to prevent future recurrence. Multiple, novel, treatment options were assessed during the outbreak, including ZMapp™ monoclonal antibody therapy, which showed promising results in some patients. However, widespread adoption of this approach is hindered by high costs of monoclonal antibody manufacturing and the relatively short half-life of antibody in the blood circulation. To circumvent such limitations, we propose to utilise recombinant adeno-associated virus (rAAV) delivered to the muscle to express the therapeutic monoclonal antibodies.

Visit

ora.ox.ac.uk

Use of Recombinant Virus Replicon Particles for Vaccination against Mycobacterium ulcerans Disease.

Buruli ulcer, caused by infection with Mycobacterium ulcerans, is a necrotizing disease of the skin

Formulation development of recombinant adenovirus-based vaccine for Newcastle disease

Kamen, Amine (Supervisor) Newcastle Disease has been causing much economic loss and food security is

A mild Theileria parva parasite with potential for immunisation against East Coast fever

Molecular Detection of Adeno and Norwalk Viruses Associated with Gastroenteritis among Juvenile in Khartoum State

Development of Bioclimatic Passive Designs for Office Building in Burkina Faso

This article focuses on adopting effective and affordable bioclimatic building design strategies in

Is health expenditure on immunisation associated with immunisation coverage in Sub-Saharan African countries?

Abstract In a bid to address the high burden of vaccine-preventable disease and lo